Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Goldman Sachs Group Inc (GS) vs Nuwellis Inc (NUWE) Price & Performance

Goldman Sachs Group IncTrade
Nuwellis IncTrade

Price performance (Past 24H)

Key statistics

Goldman Sachs Group Inc vs Nuwellis Inc — how do they compare? Goldman Sachs Group Inc trades at $1,037.43 (market cap $301.22B), while Nuwellis Inc trades at $1.51 (market cap $522.76K). The key difference: Goldman Sachs Group Inc is far larger — about 576210.9× Nuwellis Inc's market cap, and Goldman Sachs Group Inc pays a 1.93% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.

GSNUWE
Market Cap
$301.22B$522.76K
Volume
2,592,735
Sector
FinancialsTechnology
52-Week High
$1.15K$220.50
52-Week Low
$715.95$1.42
Dividend Yield
1.93%
Enterprise Value
-$1.29M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Goldman Sachs Group Inc

Goldman Sachs (GS) trades at $1,034.41, down 0.5% on the day, with a neutral technical signal. The company shows strong fundamental momentum with three consecutive quarterly EPS beats and revenue growth accelerating to $58.3B in 2025. Analyst consensus is mixed with 40% buy ratings but a $1,160 price target suggesting 12% upside potential. Recent news highlights Goldman's leadership role in major upcoming IPOs including Anthropic, SpaceX, and OpenAI.

The outlook remains positive given Goldman's positioning in the upcoming AI IPO wave and strong investment banking pipeline. Key risks include volatile cash flow patterns with negative operating cash flow in recent periods and market sensitivity to interest rate changes. The stock appears reasonably valued at 16x P/E with 31.7% net margins supporting further upside if earnings momentum continues.

Nuwellis Inc

NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.

The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Goldman Sachs Group Inc

The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.

Read more on GS

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE